0
Abstract: Poster Presentations |

Levofloxacin 750mg daily for 5 days for Community Acquired Pneumonia: Outcomes in the Elderly FREE TO VIEW

Andrew F. Shorr, MD, MPH*; Neringa Zadeikis, MD, MBA; Mohammed M. Khashab, BS; Alan M. Tennenberg, MD, MPH; E W. Ely, MD, MPH
Author and Funding Information

Walter Reed Army Medical Center, Washington, DC


Chest


Chest. 2004;126(4_MeetingAbstracts):848S-b-849S. doi:10.1378/chest.126.4.1337
Text Size: A A A
Published online

Abstract

PURPOSE:  Community-acquired pneumonia (CAP) remains a major cause of morbidity and mortality in the elderly. Nonetheless, little is known about the impact of specific antibiotic regimens on outcomes in this cohort.

METHODS:  We conducted a subgroup analysis of elderly patients (defined as age > 65 years) from a multicenter, double-blind study of CAP. In this trial, patients were randomized to treatment with either levofloxacin (L) 750 mg daily for 5 days or to L 500mg daily for 10 days. Clinical success (cure or improvement) served as the primary endpoint. Mortality assessed between days 28–31 and microbiologic eradication rates represented secondary endpoints. We also extracted data regarding safety and adverse events.

RESULTS:  The original trial included 528 patients (both outpatients and inpatients) of which 172 (32.6%) were 65 years or older. The most frequently isolated pathogens were M. pneumoniae (n=19), S. pneumoniae (n=16), and H. influenzae (n=13). Individuals receiving the 750mg regimen were slightly younger than those treated with 500mg (73.1 years vs. 75.0 years, p=0.03) but were otherwise comparable (% male: 53.8% vs. 57.6%, p=NS; median Pneumonia Severity Index class: III in both groups). Outcomes are shown in the table. 750mg500mgPClinical Success: Clinically Evaluable Patients88.5%92.2%0.49Micro-Eradication: Microbiologically Evaluable Patients90.3%87.5%0.77Mortality5.0%4.4%0.86Both regimens were well tolerated in the elderly with few serious adverse events: 11.3% for 750 mg vs. 16.7% for 500mg (p=0.31).

CONCLUSION:  In this subgroup analysis of elderly patients with CAP, treatment with 750mg L for five days performed as well as 500mg for 10 days. Both regimens were well tolerated.

CLINICAL IMPLICATIONS:  Levofloxacin 750mg daily for 5 days is a safe and effective alternative for CAP in the elderly.

DISCLOSURE:  A.F. Shorr, OMP

Wednesday, October 27, 2004

12:30 PM- 2:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543